# **Validation of SeptiCyte RAPID to discriminate sepsis from non-infectious systemic inflammation**

Robert Balk, Annette M. Esper, Greg S. Martin, Russell R. Miller III, Bert K. Lopansri, John P. Burke, Mitchell Levy, Steven Opal, Richard E. Rothman, Franco R. D'Alessio, Venkataramana K. Sidhaye, Neil R. Aggarwal, Jared A. Greenberg, Mark Yoder, Gourang Patel, Emily Gilbert, Majid Afshar, Jorge P. Parada, Jordan A. Kempker, Tom van der Poll, Marcus J. Schultz, Brendon P. Scicluna, Peter M.C. Klein Klouwenberg, Janice Liebler, Emily Blodget, Santhi Kumar, Krupa Navalkar, Thomas D. Yager, Dayle Sampson, James T. Kirk, Silvia Cermelli, Roy F. Davis, and Richard B. Brandon

## **Supplemental Information**

## Table of Contents

- 1. Gene Expression Signature: Biological Roles of PLA2G7 and PLAC8
- 2. Study Cohorts
- 3. Definitions of SIRS, Sepsis, and Comparator (Reference Method)
- 4. Organ Dysfunction as a Potential Confounding Factor
- 5. Sepsis Cases Stratified by Culture Results
- 6. Sepsis Cases Stratified by Pathogen Type
- 7. Basic Statistical Calculations
- 8. Imputation of Missing Clinical Data Values
- 9. Statistical Methods for Exploratory Data Analysis
- 10. Multivariable Analysis
- 11. Likelihood Ratio Analysis I. Selection of Variables
- 12. Likelihood Ratio Analysis II. Algorithm & Application
	- 12.1 Application to a Single Variable
	- 12.2 Extension to a Logistic Combination of Variables
	- 12.3 Application to Patient Data
	- 12.4 Sensitivity Analyses
	- 12.5 Error Propagation Analysis
- 13. References

### **1. Gene Expression Signature: Biological Roles of PLA2G7 and PLAC8**

The SeptiCyte RAPID signature measures the relative expression levels of two immunerelated mRNAs, PLAC8 (Placenta-associated 8) and PLA2G7 (Phospholipase A2 Group 7). The signature, which has two fewer biomarkers than the predicate test SeptiCyte LAB (Miller et al., 2018), was discovered using a purely bioinformatic approach, as described previously (McHugh et al., 2015).

**PLAC8** is reportedly an interferon inducible gene (Pankla et al., 2009) and is expressed in a variety of immune cells (spleen, lymph nodes), including plasmacytoid dendritic cells. It has putative roles in the optimal function of neutrophils following the uptake of bacteria (Ledford et al., 2007), the clearance of Chlamydia (Johnson et al., 2013, Johnson et al., 2012), and the host response to viral infections (Wieland et al., 2004). Related to this function is that it is expressed highly in neutrophil azurophilic granules (Velasquez et al., 2022). In sepsis, it is up-regulated across a broad range of different peripheral blood cell types including plasmacytoid dendritic and natural killer cells (Reyes et al., 2020).

**PLA2G7** encodes the protein platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme primarily produced by macrophages. This enzyme catalyzes the degradation of PAF and hydrolyses the oxidized short chain phospholipids of low-density lipoproteins (LDL), thereby releasing pro-inflammatory mediators (lysophospholipids and oxidized fatty acids). High plasma levels have been found to correlate with sepsis survival (Huang, 2018) and decreased levels have been found in sepsis (Yang et al., 2010, Gomes et al., 2006, Huang, 2020).

## **2. Study Cohorts**

Clinical validation of SeptiCyte RAPID used PAXgene blood RNA samples from retrospective ( $N=356$ ) and prospective ( $N=63$ ) patient cohorts, as described in the main text. A CONSORT diagram for all the patients is provided in **Figure S1**.



**Figure S1.** Consort diagram. Abbreviation: VENUS ext., extension of the VENUS Trial.

## **3. Definitions of SIRS, Sepsis, and Comparator (Reference Method)**

Although sepsis has been known as a medical condition since antiquity, the modern understanding of sepsis begins in the 1990s and has evolved through three phases, each characterized by a different definition (Gul et al., 2017). Interwoven through this evolution is also a consideration of SIRS, the systemic inflammatory response syndrome.

*SIRS* (Balk, 2014) - The definition of SIRS arose an American College of Chest Physicians/Society of Critical Care Medicine-sponsored 'sepsis definitions conference' held in Chicago, IL in August 1991 (Bone et al., 1992). This was the the same conference that gave rise to the Sepsis-1 definition (below). SIRS, which occurs in response to various infectious and non-infectious causes, was defined to consist of one or more of the

following factors: (1) temperature  $>38^{\circ}$ C or  $<36^{\circ}$ C; (2) heart rate  $>90$  beats per minute; (3) respiratory rate >20 breaths per minute (BPM) or PaCO<sub>2</sub> <32 mmHg; (4) white blood cell count >12,000/mm<sup>3</sup>, <4,000/mm<sup>3</sup>, or >10% immature (band) forms. Motivation for defining SIRS in this relatively non-specific way came from view that it would focus attention toward developing effective strategies to limit excessive inflammatory responses in the patient, due to various underlying causes (sepsis, trauma, burns, pancreatitis, etc.) Criticism of the SIRS definition has focused on the lack of specificity that this definition entails (Vincent et al., 2013).

*Sepsis-1* (Bone et al. 1992) - This definition arose from the same 'sepsis definitions conference' referenced above (Bone et al., 1992). Sepsis was defined as the condition occurring when 2 or more SIRS criteria are met as a consequence of infection. Severe sepsis was defined as sepsis with associated organ dysfunction. Septic shock was defined as sepsis-induced hypotension.

*Sepsis-2* (Levy et al., 2003) - documented or suspected infection, together with 2 or more SIRS-like criteria being met: temperature  $> 38.3$ °C or <36°C; heart rate >90 BPM or >2 SD above the normal value for age; respiratory rate >30 BPM; alterned mental status; significant edema or positive fluid balance; hyperglycemia in the absence of diabetes. More detailed criteria for organ dysfunction were specified. The Sepsis-2 definition could be considered a refinement and elaboration of the Sepsis-1 definition, which served as the basis for development of treatment guidelines (Levy et al., 2010).

*Sepsis-3* (Singer et al., 2016) - life-threatening organ dysfunction caused by a dysregulated host response to infection. In turn, organ dysfunction is defined as an acute increase in total Sequential Organ Failure Assessment (SOFA) score by 2 or points, as a consequence of the infection. The Sepsis-3 definition is a fairly major departure from Sepsis-1/2 in that it does not use the term 'SIRS', and emphasizes organ dysfunction. It also does not distinguish between sepsis and severe sepsis.

Another point to recognize is that, with the emphasis on organ dysfunction, a clinician operating strictly under the Sepsis-3 definition could potentially miss the early warning signs of sepsis, before organ dysfunction was obvious. This point of concern has been raised by a number of authors ( Zhang et al., 2016; Tusgul et al., 2017; Dorsett et al., 2017; Sartelli et al., 2018; Kim & Park, 2019; Lukaszewski et al., 2022), and is relevant to our own study.

Our study, which can be viewed as an extension of the previous study of Miller et al. (2018), was based on definitions of SIRS and Sepsis-2 given above. This was considered appropriate, as 240/419 (57.2%) of the samples in the present study were drawn from patients recruited in trials that predated publication of the Sepsis-3 definition: 139 subjects from the MARS trial between June 2013 and November 2013; and 101 from the VENUS trial between May 2014 and August 2015. These recruitment periods occurred before publication of the Sepsis-3 definition, which occurred on February 23, 2016 (Singer et al., 2016). Although an additional 116 subjects were recruited in the VENUS Supplement trial from March to August 2016, and an additional 63 in the NEPTUNE trial from May 2020 - April 2021, it was decided to recruit in these later trials in alignment with the SIRS and Sepsis-2 definitions, to maintain consistency with the previous MARS and VENUS recruitments.

A further consideration was that organ dysfunction (the focus of Sepsis-3) occurs at the phenotypic level, as modulated by protein structure & function, whereas SeptiCyte RAPID is a gene expression-based assay. Changes in gene expression occur some hours before changes in protein expression occur. By this logic, the Sepsis-2 definition would appear more appropriate for our study, than the Sepsis-3 definition. A similar argument has been made by Lukaszewski et al. (2022), in support of their own gene expression study.

To define the "Ground Truth" for our study, an external three-member panel of experienced physicians not involved in the clinical care of the patients performed a threeway patient classification (sepsis, SIRS or indeterminate) by chart review in accordance

with the SIRS and Sepsis-2 definitions (Levy et al., 2003). This approach follows the general framework defined by Klein-Klouwenberg and colleagues for employing an expert panel for assigning infection probability estimates in studies on sepsis (Klein-Klouwenberg et al., 2012; 2013; 2015; Lopansri et al., 2019). Three algorithms for this Retrospective Physician Diagnosis (RPD) process were used:

*Consensus:* Two or three RPD panelists agreed that a patient had either sepsis or SIRS. Indeterminates, which occured when two or three panelists made a call of 'indeterminate' or when all three panelists disagreed, were excluded.

*Unanimous:* All three RPD panelists agreed that a patient had either sepsis or SIRS. (A unanimous call of indeterminate was also theoretically possible.)

*Forced:* When a patient was initially called "indeterminate" by the RPD panelists, the panelists were then forced to make a consensus or unanimous call of sepsis or SIRS.

The RPD panelists received a data package for each patient, consisting of 39 data elements as specified in **Table S1**.

No.	<b>Description</b>			
<b>1. DEMOGRAPHICS</b>				
$\mathbf{1}$	Age of subject			
$\overline{2}$	Race of subject			
3	Sex of subject			
$\overline{4}$	Source of patient, pre-ICU admission			
2. VITAL SIGNS				
5	Minimum mean arterial blood pressure (MAP min)			
6	Maximum mean arterial blood pressure (MAP max)			
7	Minimum measured body temperature			
8	Maximum measured body temperature			

**Table S1.** Clinical data elements made available to the RPD panelists (per patient).





## **4. Organ Dysfunction as a Potential Confounding Factor**

A question arising in the use of the Sepsis-2 definition (as opposed to the Sepsis-3 definition) is whether organ dysfunction is a confounding factor in the interpretation of SeptiScores. In our previous paper on the 4-gene SeptiCyte LAB signature (McHugh et al., 2015) we examined the question of whether organ dysfunction was a potential confounder of the SeptiScore. The conclusion we reached (Figure 5 therein) was that "with respect to discrimination of cases from controls by SeptiCyte Lab, any confounding effect of disease severity, as measured by APACHE IV or SOFA score, appeared small".

We conducted a similar analysis, using the 2-gene SeptiCyte RAPID signature (derived from the SeptiCyte LAB 4-gene signature) and the newly generated dataset, stratified by SOFA score. The results of the new analysis are shown in **Figure S2**. In Panel A, the SeptiScores for sepsis vs. SIRS are stratified on the basis of SOFA score. In Panel B, the same stratification is done for procalcitonin (PCT) to allow comparison to SeptiScore. In Panel C, the SeptiScore AUC for sepsis vs. SIRS discrimination is plotted as a function of SOFA score, using a "sliding window" approach (Arsu & Manku, 2004).

As before for SeptiCyte LAB, we see little if any significant dependence of the SeptiScore on SOFA score. We interpret this to mean that SeptiCyte RAPID is not measuring or responding to the 'organ dysfunction' aspect of sepsis, but rather to some other characteristic of the process, possibly occuring earlier than organ dysfunction. A similar conclusion was reached for a different gene expression signature proposed for sepsis diagnosis (Lukaszewski et al., 2022).

**Figure S2**. SeptiScore as function of SOFA score. (A, B) SeptiScores and procalcitonin (PCT) values, respectively, for sepsis vs. SIRS groups, parsed into different SOFA bins. Forced RPD was used for the sepsis vs. SIRS assignments, and only those patients having both SeptiScores and PCT values were used. (C) SeptiScore AUC for the sepsis vs. SIRS discrimination, as a function of the SOFA sliding window position.



## **5. Sepsis Cases Stratified by Culture Results**

**Figure S3** presents a stratification of patients with respect to both the sepsis/SIRS assessment by consensus RPD (with 41 indeterminates not counted), and also whether pathogen identification by culture or PCR was obtained or not. Thus we find that, of the 154 patients called septic by consensus RPD, 31 did not have positive culture or PCR results. However, these were still discriminated significantly away from SIRS, with AUC  $= 0.75$  (p = 4.82 x 10<sup>-5</sup>). It is perhaps unsurprising that culture/PCR-positive sepsis cases would tend toward higher AUC values than culture/PCR-negative sepsis cases. Likely explanations would include: (1) that culture-positive sepsis exhibits a more pronounced inflammatory response to presence of more 'pathogen-associated molecular pattern molecules' (PAMPs); and (2) that positive culture results would influence the RPD decision process more towards a sepsis diagnosis.

**Figure S3.** Stratification of patient cohort according to diagnosis by consensus RPD, and by culture or PCR findings. The first dimension is diagnosis of sepsis or SIRS by consensus RPD (with indeterminates excluded).The second dimension is whether positive or negative results were returned by microbiological culture for bacteria or fungi, or by PCR (or RT-PCR) for viruses.



### **6. Sepsis Cases Stratified by Pathogen Type**

Out of 419 ICU patients, there were 154 (36.8%) sepsis cases according to Consensus RPD. Of these, 100 (64.9%) were considered to have one or more identifiable pathogens (bacterial, fungal, viral) as the underlying causative agent(s). **Figure S4** represents the distribution of identified pathogens by means of pie charts, with panel (A) at the level of bacterial, viral, fungal pathogens and panel (C) at the level of bacterial genera and species. The remaining panels (B) and (D) show the SeptiScore distributions for patients with bacterial vs. mixed (bacterial/viral/fungal) infections (Panel B), and for patients with Gram (-) vs. Gram (+) bacterial infections (Panel D). No significant differences in SeptiScore distributions were found in the comparisons in either panel. Thus SeptiScore does not appear to be significantly affected by the type of pathogen underlying a sepsis event.

**Figure S4.** Septic patients stratified by pathogen type and bacterial species. Sepsis diagnosis was by consensus RPD. Only those septic patients with pathogens identified by culture or PCR are represented  $(N=100)$ . (A) Pie chart for pathogens by type (bacterial,

viral, fungal). (B) Cumulative SeptiScore distributions for patients with identified bacteria (N=89) vs. acute viral, fungal or mixed infections (N=13). A Kolmogorov-Smirnov test indicates no significant difference  $(p=0.375)$ . (C) Pie chart for bacteria by species. (D) Cumulative SeptiScore distributions for patients with identified Gram positive (N=55) vs. Gram negative (N=36) infections. A Kolmogorov-Smirnov test indicates no significant difference  $(p=0.264)$ . Pie charts were drawn with the R package ggplot2.



The observed distributions of the most commonly occurring pathogen types found in sepsis-associated positive cultures (not restricted to blood cultures) is listed **Table S2.** For context, this table also shows the corresponding frequencies observed in blood cultures from hospitalized US patients (taken from a large survey study of 82,569

bacterial blood culture isolates reported to The Surveillance Network (TSN) Database-USA by 268 laboratories; Karlowsky et al., 2004).

Pathogen	Observed in sepsis	Karlowsky et al.
	cases, present study*	(2004) blood culture
Gram $(+)$ only	31	--
Gram (-) only	30	$-$
Gram $(+/-)$ (both)	26	$-$
Bacterial/viral	8	$-$
Bacterial/fungal	4	$-$
Staphylococcus aureus	34 (including 9 MRSA)	16.5 %
Escherichia coli	25	$7.2\%$
Pseudomonas aeruginosa	12	$2.5\%$
Klebsiella spp.	9	$3.6\%$
Enterococcus faecalis	8	8.3 %
Proteus spp.	5	$0.9\%$
Bacteroides fragilis	3	${}< 0.2\%$
Enterococcus faecium	3	$3.5\%$
Candida spp.	$\overline{3}$	$< 0.2\%$
Streptococcus pneumoniae	$\overline{2}$	2.3 %
Clostridium dificile	$\overline{2}$	$< 0.2\%$
Clostridium perfringens	$\overline{2}$	$< 0.2\%$
Corynebacterium spp.	$\overline{2}$	$< 0.2\%$
Citrobacter freundii	$\overline{2}$	$0.3\%$

**Table S2.** Breakdown of specific pathogen genera and species (present at >1%), isolated in cultures from septic patients (N=100 patients total). Sepsis diagnosed by consensus RPD.

There were six SARS-CoV-2 positive patients in the prospective cohort, five of whom were called septic and one SIRS by consensus RPD. In Figure 2B (main text), the prospective cohort ROC curves for forced (black), consensus (blue) and unanimous (red) RPD, had  $AUC = 0.86$ , 0.90 and 0.95 respectively. When the six COVID-19 patients were removed from the prospective cohort and the AUC analyses repeated, no significant effect was found  $(AUC = 0.85, 0.90, 0.98$  for forced, consensus, unanimous RPD respectively).

## **7. Basic Statistical Calculations**

Sepsis probability as a function of SeptiScore was calculated by a "sliding window" approach (Arsu & Manku, 2004). Briefly, a custom R script was written to conduct a sliding window calculation of the probability of sepsis P(sepsis) across the 0-15 SeptiScore range. The sliding window was 4 score units wide, and was shifted in 1-unit increments from the lower to the upper limit of the SeptiScore range. In each 4-unit wide window, the numbers of sepsis calls  $(N_{\text{sensus}})$  and SIRS calls  $(N_{\text{SIRS}})$  were tabulated according to each RPD method, and the sepsis probability  $P = (N_{\text{sepsis}}) / (N_{\text{sepsis}} + N_{\text{SIRS}})$ was computed for that window. The process was repeated stepwise over the entire 0-15 SeptiScore range.

Sepsis probability as a function of SeptiScore was parsed into four bands, with higher SeptiScores representing higher probabilities of sepsis. Band boundaries were predefined, based on an independent set of 195 clinical samples from the MARS consortium, to give 90% sensitivity for binarization at the Band 1/2 cutoff (SeptiScore 4.95) and 80% specificity for binarization at the Band 3/4 cutoff (SeptiScore 7.45), using site clinical adjudications as Ground Truth values. The intermediate zone between the Band 1/2 and Band 3/4 cutoffs was divided in half to define the Band 2/3 cutoff (SeptiScore 6.15).

Receiver-Operating Characteristic (ROC) curve analysis was performed in accordance with Clinical and Laboratory Standards Institute EP24-A2 using the pROC package (Robin et al., 2011). Other clinical performance measures (clinical sensitivity, clinical specificity, sepsis and SIRS probabilities, and likelihood ratios) were also calculated.

## **8. Imputation of Missing Clinical Data Values**

For the individual clinical laboratory variables, data were collected over the 24 hour period following ICU admission. Missing values were imputed using a multiple imputation algorithm, Amelia (Honaker et al., 2011) (**Table S3**). Multiple imputation reduces bias and increases accuracy over point-imputation methods such as "mean" or "median" imputation. Amelia produces  $n_{\text{imputed}}$  datasets which are then processed with downstream algorithms as needed. In this case, *nImputations* was set to 5.

Note: the #(SIRS criteria observed at enrollment) was calculated on the basis of clinical data recorded over the 24 hour study enrollment period. This quantity is calculated as a sum of points with 1 point for each of the following:

- Heart Rate  $> 90$  beats / minute
- Respiratory Rate > 20 breaths / minute
- Core temperature  $<$  36.0 °C or  $>$  38.0 °C
- White Blood Cell count  $\leq 4.000/\mu L$  or  $\geq 11.000/\mu L$  or % Bands  $\geq 10\%$

In order for a patient to be enrolled in the study, calculation of the #(SIRS criteria at enrollment) was necessary. Therefore, there are no missing values for this parameter.

The 24 hour study enrollment period precedes and partially overlaps the first 24 hours after ICU admission. Thus, although the #(SIRS criteria observed at enrollment) must have been recorded for the patient to have been enrolled in the study, data for some of the clinical laboratory variables may not have been not recorded during the first 24 hours after ICU admission, leading to missing values in the clinical line data file.



**Table S3.** Imputation of missing values in the clinical line data, by means of the Amelia software package.



## **9. Data Subsets and Statistical Methods for Exploratory Data Analysis**

Different subsets of the line data file were considered, depending upon the particular analysis being done (**Table S4**).

Balk R et al. Validation of SeptiCyte RAPID for sepsis vs. SIRS - Online data supplement

**Table S4.** Utilization of clinical variables in downstream analyses. Single variable performance (AUC) was evaluated for the sepsis vs. SIRS comparison, with no values imputed, and with consensus RPD as reference. Fig. 5 and Fig. 6 refer to figures in the main text. ND = not determined (categorical variable).







 $*$  not included in the multivariable analysis, because there were too many missing values ( $>$ 30%)

\*\* minimum blood glucose was not included in the multivariable analysis of Figure 6 in the main text, because hypoglycemia is not associated with sepsis mortality, while hyperglycemia is (Lu et al., 2022).

### **10. Multivariable Analysis**

A custom R script was written to evaluate the classification performance of all 32,767 possible combinations of SeptiScore with any of the 14 clinical variables specified in column 4 of **Table S4**. AUC was used as performance measure with Consensus RPD as comparator.

The algorithm used for multivariable analysis consists of the following steps:

Step 1. As indicated in **Table S4**, 13 of the 39 variables used in the RPD process were employed in the multivariable analysis, as they satisfied the following criteria:

- 1) routinely used as a diagnostic aid in the differential diagnoses of sepsis;
- 2) routinely available in the first 24 hours after ICU admission;
- 3) no more than 30% missing values requiring imputation.

Procalcitonin and SeptiScore were also used, making 15 variables in all.

Step 2. The data were partially incomplete. Missing values were imputed with Amelia [ref. E5] which is a multiple imputation algorithm that produces  $n_{\text{imputed}}$  datasets, which can then be processed with downstream algorithms as needed. It has been argued that multiple imputation reduces bias and increases accuracy over point-imputation methods such as "mean" or "median" imputation (Honaker et al., 2011). In this case,  $n_{\text{Imputation}}$ was set to 5.

Step 3. From the pool of 15 variables listed in Table S4, all possible unordered subsets of variables were defined, with no repetitions. Each such combination consisted of 1 to 15 variables. The total number of possible combinations is given by the following formula:

$$
\Sigma_{j=1}^{15} {15 \choose j} = \Sigma_{j=1}^{15} \frac{15!}{(j!)(15-j)!} = 32,767
$$
 (Eq. S1)

Step 4. For each possible combination of variables, a multivariable model was constructed by logistic regression, and the AUC was calculated with consensus RPD as the comparator.

Step 5. The distribution of AUC for all models was plotted (**Figure 5** in main text) by dividing into three histograms for (i) models not containing SeptiScore or PCT, (ii) models containing PCT but not SeptiScore, and (iii) models containing SeptiScore (which may also include PCT).

### **11. Likelihood Ratio Analysis I. Selection of Variables**

We used the Random Forest wrapper Boruta (Kursa & Rudnicki, 2010) to achieve an initial down-selection of variables for subsequent use in likelihood ratio analysis. An initial set of 23 variables was selected for input to a Random Forest analysis using the Boruta wrapper. Column 5 in **Table S4** summarizes the variables that were selected. For this analysis, the complete validation dataset  $(356$  retrospective  $+ 63$  prospective) was used with Forced RPD as comparator.

With Boruta, the name (label) assigned to a variable is called an 'attribute' and the measured value of a variable is called a 'response'. The dataset used for Random Forest classification is 'extended' by creating shadow attributes which are random, shuffled combinations of the original attributes (variable names) with the responses (measured values).

The trees in the Random Forest are developed on different sub-samples of the data. The importance of an attribute is equated with the loss of classification accuracy caused by the random shuffling process. This is calculated separately for every tree in the forest that uses a given attribute for classification.

Z-scores are computed when running random forest classification and the Z-scores of every real attribute are compared with the maximum Z score from the shadow attributes. A hit is recorded every time the Z-score of a real attribute is higher than the maximum Z

22

score from the shadow attributes. Attributes whose Z-score is statistically significantly lower than the maximum Z-score from the shadow attributes are assigned the value 'rejected' and removed at every iteration of the random forest classification. Attributes with a statistically significantly higher Z-score than the maximum Z-score from shadow attributes are assigned the value 'confirmed'. Attributes that are not assigned importance within a pre-set number of iterations (99 by default) are assigned the value 'tentative'. These tentative attributes are re-classified as confirmed or rejected by comparing the median Z score of attributes with the median Z-score of the best shadow attribute when using the 'TentativeRoughFix' method as implemented in the Boruta R package. The confirmed attributes are then sorted, based on their median importance.Tentative attributes get re-classified as confirmed or rejected by comparing the median Z score of attributes with the median Z-score of the best shadow attribute.

**Figure S5.** Boruta Random Forest analysis. RPD = forced (176 sepsis, 243 SIRS). In this figure, the blue boxes correspond to minimum, mean and maximum Z scores of shadow attributes. The red and green boxes, respectively, represent Z scores of rejected and confirmed attributes.



The variables identified as significant in the Boruta analysis (green boxes in Figure E2) were then reanalyzed by the Kolmogorov-Smirnov test, as an independent check for significance in discriminating between sepsis and SIRS. In this test, parameters that displayed a significant vertical offset between cumulative score distribution curves for sepsis vs. SIRS were considered to be significant. Results from the Kolmogorov-Smirnov analysis are summarized in **Table S5**. Five of the variables identified by Boruta (WBC max, Bands % min, CRP, lactate, SOFA score) were considered by Kolmogorov-Smirnov to be insiginficant at the p<0.05 level, and therefore were not taken forward into the subsequent likelihood ratio analysis.

**Table S5.** Kolmogorov-Smirnov analysis of variables for discriminating sepsis vs. SIRS. The complete validation dataset  $(356$  retrospective + 63 prospective) was used for calculations, with Forced RPD as comparator. The Kolmogorov-Smirnov test was conducted using the applet available at the following website:

http://www.physics.csbsju.edu/stats/KS-test.html. Values of the Kolmogorov-Smirnov D statistic and corresponding probabilities (p-values) are shown.

Variable	<b>N SIRS</b>	N sepsis	N total	D	p-value
1. SeptiCyte RAPID	243	176	419	0.5407	${}_{0.001}$
2. PCT	198	149	347	0.4842	${}_{0.001}$
3. TEMP max	209	157	366	0.2353	${}_{0.001}$
5. SIRS criteria	243	176	419	0.2291	${}_{0.001}$
11. Respir Rate max	172	123	295	0.2238	0.001
8. MAP min	236	175	411	0.1885	0.001
9. WBC min	236	171	407	0.1743	0.004
6. WBC max	234	169	403	0.1677	0.007
10. Bands % min	32	31	63	0.4002	0.009
4. CRP	14	32	46	0.3973	0.068
12. lactate	150	129	279	0.1295	0.181
7. SOFA	159	131	290	0.1140	0.290

The significance of a variable by the Kolmogorov-Smirnov test can be easily confirmed by visual inspection of the cumulative distributions of sepsis and SIRS patients, shown e.g. for the SeptiScore in **Figure S6**.

**Figure S6.** Cumulative distribution curves for the SeptiScore. There were 243 SIRS datapoints and 176 sepsis datapoints with SeptiScore values available  $(417/419 = 100.0\%$ of all patients in cohort).



### **12. Likelihood Ratio Analysis II. Algorithm & Application**

We used a likelihood ratio (LR) approach to adjust sepsis probabilities, by taking into account diagnostic information provided by clinical parameters. References for this approach include Fagan, 1975; Gallagher, 1998; Deeks & Altman, 2004; Parikh et al., 2009.

### **12.1 Application to a Single Variable**

Consider patients in our clinical trials, evaluated by Forced RPD. The patients are categorized as either sepsis or SIRS. In the absence of any diagnostic test results, the odds of a patient having sepsis is defined as follows:

$$
p\sigma / (1-p\sigma) = p(\text{sepsis}) / p(\text{SIRS}) = \#(\text{sepsis}) / \#(\text{SIRS})
$$
 (Eq. S2).

In Eq. (S2) the subscript "o" indicates an assumed value for sepsis probability, in the absence of test results. In our study cohort, a total of 176 patients were diagnosed with sepsis by Forced RPD. Therefore  $po = 176/419 = 0.42$  and  $po/(1-po) = 176/(419-176) =$  $176/243 = 0.724$ .

The likelihood ratio is used to evaluate how knowledge of a test result changes the perceived odds that a patient has sepsis vs. SIRS.

The likelihood ratio is defined as follows (Deeks & Altman, 2004):

 $LR =$ ratio of the probability (p) of a specific test result in patients who have the condition (sepsis), to the probability (1-p) of that same test result in patients who do not have the condition.

 $LR_1$  for a given test #1 is defined over a particular range of test results, for example SeptiScores in Band 4, and is estimated as follows:

$$
LR_1 = p_1/(1-p_1) = \frac{\frac{\#(sepsis) \text{ in range}}{\text{all steps}}}{\frac{\#(SIRS) \text{ in range}}{\text{all SIRS}}}
$$
(Eq. S3)

For the variables identified as significant by both the Boruta and Kolmogorov-Smirnov analyses, we use a sliding window approach (Arasu & Manku, 2004) to calculate likelihood ratio (LR) functions. This is done in several steps:

Step 1. For a particular variable of interest (for example SeptiScore) the patients are ranked from low to high.

Step 2. In a sliding window 50 patients wide, the number of SIRS and sepsis patients in the window are recorded (see **Figure S7** below, for SeptiScore as an example).

Step 3. The number of SIRS patients in the window is converted to % SIRS, by dividing this number by the total number of SIRS patients (in the full cohort) who have values available for the variable of interest.

Step 4. The same process as in step 3 is carried out, for the sepsis patients.

Step 5. The % SIRS and % sepsis are then used to calculate the LR for the particular window position, according to Eq.  $(S3)$ .

Step 6. The sliding window is then moved one position, the LR is recalculated, and so on.

Step 7. A plot of LRs versus patient rank is thus obtained (see **Figure S6** for SeptiScore as an example).

Step 8. The LR datapoints are then fit empirically to a mathematical function, and the goodness-of-fit is evaluated by analysis of residuals (see **Figure S7** for SeptiScore as an example). If the fit is deemed acceptable, then the mathematical function is used in subsequent calculations.

**Figure S7**. Number of SIRS and sepsis patients, per (50 patient wide) sliding window defined by SeptiScore. The patients were first ordered by increasing SeptiScore, and then a 50-patient window was moved up the patient rank. The first window covered patients # 1-50, the second window covered patients # 2-51, etc. Because Forced RPD is used as comparator, a patient must be classified as either SIRS or sepsis, and therefore the  $N<sub>SIRS</sub>$  $+$  N<sub>sepsis</sub> = 50 for each 50-patient window.



**Figure S8.** Likelihood ratio (LR) plot for the SeptiScore. (A) The empirical best-fit equation is an exponential function, with x = SeptiScore, LR=10<sup>y</sup> and y =  $0.0168x^2$  + 0.1047x - 1.3376. For the fit shown in this graphic,  $R^2 = 0.93811$ .



**Figure S9.** Plot of residuals for the equation described in Figure S8, in log space, centered around zero. The empirical best-fit equation is an exponential function, with  $x =$ SeptiScore, LR=10<sup>y</sup> and y =  $0.0168x^2 + 0.1047x - 1.3376$  and R<sup>2</sup> = 0.93811.



### **12.2 Extension to a Logistic Combination of Variables**

An extension of the preceding approach is to combine significant variables together in a logistic regression function, and then to perform a sliding-window analysis using this function.

A logistic regression analysis, based on the variables identified as significant by Boruta and Kolmogorov-Smirnov, produces the following function, as having the least-squares optimum fit to the data:

 $y = 26.019 - 0.326$  (SIRS criteria) + 0.0046 (MAP Min) - 0.539 (T max) - 0.0407 (RR max) - 0.029 (WBC Min) - 0.249 (log<sub>2</sub> PCT) - 0.524 (SeptiScore)

Eq. (S4).

Here, y is a continuous valued function which has lower values for sepsis and higher values for SIRS. The cumulative distribution plot and Kolmogorov-Smirnov test result for this function is shown in **Figure S10**.

**Figure S10.** Cumulative distribution plots for sepsis vs. SIRS, using the logistic regression function given by Eq.  $(S4)$ . The Kolmogorov-Smirnov D statistic = 0.634, with  $p < 2.2 \times 10^{-16}$ , for separation between the two cumulative distributions.



**Figure S11** shows the shift in the sepsis and SIRS patient numbers in a 50-patient wide sliding window, as the sliding window is moved along the ranked patient list from low to high values of the logistic regression function.

**Figure S11.** Number of SIRS and sepsis patients, per (50 patient wide) sliding window defined by the logistic regression function given by Eq. (S4).



**Figure S12** shows a plot of the likelihood ratio (LR) versus the logistic regression function of Eq. (S4). The points in this plot represent the empirical LR calculated with a 50-patient wide sliding window. There are three 'zones' in this plot:

- high LR zone: all points with logistic regression function  $x < -3.94$  have an (average) likelihood ratio of 67.65
- LR sensitivity zone: described by equation  $y = 0.8163 e^{-1.042x}$  with coefficient of determination  $R^2 = 0.982$
- low LR zone: all points with logistic regression function  $x > +1.954$  have an (average) likelihood ratio of 0.164

**Figure S12:** Plot of likelihood ratio (LR) versus the logistic regression function given by Eq. (S4). Blue points: empirical. Red points: empirical points used for least-squares fitting in the 'LR sensitivity zone'.



We compared the post-test probabilities of sepsis, computed from the empirical LRs (one for each sliding window), versus the post-test probabilities computed using the analytical function LR=10<sup>y</sup> and y = 0.0168x<sup>2</sup> + 0.1047x - 1.3376, where x = SeptiScore. This function represents an 'idealized' fit of the LR estimates across all 50 patient wide sliding windows. Results are shown in **Figure S13**. There is strong linear correlation between the two estimates ( $R^2$  =0.95751). However, the correlation is not perfect and there appear to be regions of the plot where deviations are not random.

**Figure S13.** Scatterplot of the post-test probability of sepsis, after applying SeptiCyte RAPID, as estimated by empirical vs. analytical method. x-axis: Post-test sepsis probability, when likelihood ratios (LR) are estimated empirically using a 50-patient wide sliding window. y-axis: Post-test sepsis probability, when likelihood ratios (LR) are estimated analytically, using the function  $LR=10^y$  and  $y = 0.0168x^2 + 0.1047x - 1.3376$ , where  $x =$  SeptiScore.



### **12.3 Application to Patient Data**

We next applied this logistic function to the sepsis probability analysis of selected individual patients. Results are shown in **Figure 6** and **Table 5** in the main text, for three patients who were called septic by Forced RPD, and three patients who were called SIRS by Forced RPD. We observe the largest impact from SeptiScore. When we employ the logistic model with SeptiScore + additional 6 parameters (Eq. S4) there is a relatively small but still significant further diagnostic impact.

### **12.4 Sensitivity Analyses**

We conducted a sensitivity analysis, to determine the importance of the width of the sliding window used in our approach. We focus on just the SeptiScore component, with the understanding that the findings will probably also apply to the other components.

We varied the width of the sliding window, performed a least-fit to the resultant empirical  $log_{10}(LR)$  values, and observed the variation in the coefficient of determination  $(R<sup>2</sup>)$  for the fit. Results of this analysis for the SeptiScore are presented in **Table S7**. The

analysis indicates that the fit is stable over the 30-60 window width range, but becomes unstable below a window width of 30.

**Table S6.** Sensitivity analysis of sliding window width for SeptiScore. The complete (N=419) dataset was used, with Forced RPD. The empirical LR values were fit to the following equation:  $log_{10}(LR) = ax^2 + bx + c$ .

<b>Window</b>	a	$\mathbf b$	$\mathbf c$	$R^2$
Width				
20	0.0109	0.1652	$-1.5455$	0.85981
25	0.0132	0.1454	$-1.5133$	0.88861
30	0.0171	0.0933	$-1.3354$	0.90811
40	0.0173	0.0950	$-1.3257$	0.93223
50	0.0168	0.1047	$-1.3376$	0.98311
60	0.0165	0.1096	$-1.3298$	0.94260

#### **12.5 Error Propagation Analysis**

Clearly there are deviations between the empirical LR and the analytically defined LR. What is the basis for these deviations? Consider the following equation:

Observed  $LR = True LR$  + RPD bias + small N fluctuation + measurement error Eq. (S5)

Suppose (for the sake of argument) that the True LR is represented by the best-fit analytical function.

The RPD bias term relates to imperfection in the comparator and can be revealed by discordance analysis. This term will produce a systematic shift of points in the vertical (LR) dimension, in the likelihood ratio plots.

The small N fluctuation term arises because of the small number of sepsis and SIRS samples in the sliding window calculation of LR. This term will produce random fluctuation of points in the vertical (LR) dimension in the likelihood ratio plots. In the calculations performed here, we have set the sliding window at 50 patients wide, which represents an attempt to put reasonable bounds on this error term.

The measurement error term arises because the clinical parameters are represented by physical measurements of some sort, which of necessity will carry some measurement error. This will produce random fluctuations along the horizontal (parameter) dimension, in the likelihood ratio plots.

## **13. References**

Arasu A & Manku GS (2004) Approximate Counts and Quantiles over Sliding Windows. PODS 2004: Proceedings of the twenty-third ACM SIGMOD-SIGACT-SIGART symposium on principles of database systems, June 14-16, 2004. Pages 286–96. DOI: 10.1145/1055558.1055598

Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014;5(1):20-6. DOI: 10.4161/viru.27135.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55. DOI: 10.1378/chest.101.6.1644.

Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168–9. DOI: 10.1136/bmj.329.7458.168

Dorsett M, Kroll M, Smith CS, Asaro P, Liang SY, Moy HP. qSOFA has poor sensitivity for Prehospital identification of severe sepsis and septic shock. Prehosp Emerg Care. 2017:1–9. DOI: 10.1080/10903127.2016.1274348.

Fagan TJ. Nomogram for Bayes theorem. N Engl J Med. 1975; 293:257. DOI: 10.1056/NEJM197507312930513.

Gallagher EJ. Clinical utility of likelihood ratios. Ann Emerg Med. 1998;31:391-7. DOI: 10.1016/s0196-0644(98)70352-x.

Gomes RN, Bozza FA, Amancio RT, Japiassu AM, Vianna RC, Larangeira AP, et al. Exogenous platelet- activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock. 2006; 26:41–9. PMID: 16783197. DOI: 10.1097/01.shk.0000209562.00070.1a.

Gül F, Arslantaş MK, Cinel İ, Kumar A. Changing Definitions of Sepsis. Turk J Anaesthesiol Reanim. 2017;45(3):129-38. DOI: 10.5152/TJAR.2017.93753.

Honaker J, King, G, Blackwell M. (2011). Amelia II: A Program for Missing Data. J Stat Soft. 2011;45:1–47. DOI: 10.18637/jss.v045.i07.

Huang Z, Jiang H, Cui X, Liang G, Chen Y, Wang T, Sun Z, Qi L. Elevated serum levels of lipoprotein-associated phospholipase A2 predict mortality rates in patients with sepsis. Mol Med Rep. 2018;17(1):1791-8. DOI: 10.3892/mmr.2017.8034.

Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020;40(1):79-134. DOI: 10.1002/med.21597.

Johnson RM, Kerr MS, Slaven JE. Perforin is detrimental to controlling C. muridarum replication in vitro, but not in vivo. PLoS ONE. 2013; 8:e63340. DOI: 10.1371/journal.pone.0063340.

Johnson RM, Kerr MS, Slaven JE. Plac8-dependent and inducible NO synthasedependent mechanisms clear Chlamydia muridarum infections from the genital tract. J Immunol. 2012; 188:1896–1904. DOI: 10.4049/jimmunol.1102764.

Karlowsky JA, Jones ME, Draghi DC, Thornsberry C, Sahm DF, Volturo GA. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob. 2004;3:7. DOI: 10.1186/1476-0711-3-7.

Kim HI, Park S. Sepsis: Early Recognition and Optimized Treatment. Tuberc Respir Dis (Seoul). 2019;82(1):6-14. DOI: 10.4046/trd.2018.0041.

Klein Klouwenberg PM, Cremer OL, van Vught LA, Ong DS, Frencken JF, Schultz MJ, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care. 2015;19(1):319. DOI: 10.1186/s13054- 015-1035-1.

Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. Intensive Care Med. 2012;38(5):811-9. DOI: 10.1007/s00134- 012-2549-5.

Klein Klouwenberg PM, Ong DS, Bos LD, de Beer FM, van Hooijdonk RT, Huson MA, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013;41(10):2373-8. DOI: 10.1097/CCM.0b013e3182923712.

Kursa MB and Rudnicki WR. Feature Selection with the Boruta Package. J Stat Soft. 2010;36:1-11. DOI: 10.18637/jss.v036.i11.

Ledford JG, Kovarova M, Koller BH. Impaired host defense in mice lacking ONZIN. J Immunol. 2007;178:5132–5143. DOI: 10.4049/jimmunol.178.8.5132.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. Crit Care Med. 2003;31:1250–1256. DOI: 10.1097/01.CCM.0000050454.01978.3B.

Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med*.* 2010;38:367–74. DOI: 10.1097/ccm.0b013e3181cb0cdc.

Lopansri BK, Miller III RR, Burke JP, Levy M, Opal S, Rothman RE, et al. Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort. J Intensive Care. 2019;7:13. DOI: 10.1186/s40560-019-0368-2.

Lu Z, Tao G, Sun X, Zhang Y, Jiang M, Liu Y, et al. Association of Blood Glucose Level and Glycemic Variability With Mortality in Sepsis Patients During ICU Hospitalization. Front Public Health. 2022;10:857368. DOI: 10.3389/fpubh.2022.857368.

Lukaszewski RA, Jones HE, Gersuk VH, Russell P, Simpson A, Brealey D, et al. Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures. Intensive Care Med. 2022;48(9):1133-1143. DOI: 10.1007/s00134-022- 06769-z.

Marshall JC. Sepsis-3: What is the Meaning of a Definition? Crit Care Med. 2016;44(8):1459-60. DOI: 10.1097/CCM.0000000000001983.

Miller RR 3rd, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. Am J Resp Crit Care Med. 2018;198:903- 913. DOI: 10.1164/rccm.201712-2472OC.

Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, Banchereau J, et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 2009; 10:R127. DOI: 10.1186/gb-2009-10-11-r127.

Parikh R, Parikh S, Arun E, Thomas R. Likelihood ratios: clinical application in day-today practice. Indian J Ophthalmol. 2009;57:217-221. DOI: 10.4103/0301-4738.49397.

Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26(3):333-340. DOI: 10.1038/s41591-020-0752-4.

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C et al. pROC: an opensource package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. DOI : 10.1186/1471-2105-12-77.

Sartelli M, Kluger Y, Ansaloni L, Hardcastle TC, Rello J, Watkins RR, et al. Raising concerns about the Sepsis-3 definitions. World J Emerg Surg. 2018;13:6. DOI: 10.1186/s13017-018-0165-6.

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. DOI: 10.1001/jama.2016.0287.

Tusgul S, Carron PN, Yersin B, Calandra T, Dami F. Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. Scand J Trauma Resusc Emerg Med. 2017;25(1):108. DOI: 10.1186/s13049-017-0449-y.

Velásquez SY, Coulibaly A, Sticht C, Schulte J, Hahn B, Sturm T, et al. Key Signature Genes of Early Terminal Granulocytic Differentiation Distinguish Sepsis From Systemic Inflammatory Response Syndrome on Intensive Care Unit Admission. Front Immunol. 2022;13:864835. DOI: 10.3389/fimmu.2022.864835.

Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381(9868):774-5. DOI: 10.1016/S0140-6736(12)61815-7.

Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA. 2004; 101:6669–6674. DOI: 10.1073/pnas.0401771101.

Yang J, Xu J, Chen X, Zhang Y, Jiang X, Guo X, et al. Decrease of plasma plateletactivating factor acetylhydrolase activity in lipopolysaccharide induced Mongolian gerbil sepsis model. PLoS ONE. 2010; 5:e9190. DOI: 10.1371/journal.pone.0009190.

Zhang Z, Smischney NJ, Zhang H, Van Poucke S, Tsirigotis P, Rello J, et al. AME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital. J Thorac Dis. 2016;8(9):2654-2665. DOI: 10.21037/jtd.2016.08.03.